{"success":true,"data":{"pressRelease":{"id":"177794","rtpr_id":"nGNX1CkbQL-20261022","ticker":"CVRX","exchange":"NASDAQ","all_tickers":["CVRX"],"title":"CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026","author":"Globe Newswire","published_at":"2026-10-22T20:30:00.261Z","article_body":"MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX)\n(\"CVRx\"), a commercial-stage medical device company focused on developing,\nmanufacturing and commercializing innovative neuromodulation solutions for\npatients with cardiovascular diseases, today announced that it plans to\nrelease third quarter 2026 financial and operating results after market close\non Thursday, Nov. 5, 2026. The Company will host a conference call to review\nits results at 4:30 p.m. Eastern Time the same day.\n\nA live webcast of the investor conference call will be available online at the\ninvestor relations page of the Company’s website at ir.cvrx.com\n(https://www.globenewswire.com/Tracker?data=zbDHhvjFdAqnHPL9dXgOVeF-QBSw1NRH1u0aOntIMsGOR5KtUJdnBEdcipZwstN__E0nUP-3HqX6ZbqlIZnjPfNS-TBoKeIo_nzMAYF753s=).\nTo listen to the conference call on your telephone, please dial 1-\n877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers,\napproximately ten minutes prior to the start time.\n\nAbout CVRx, Inc.\nCVRx is a commercial-stage medical device company focused on developing,\nmanufacturing and commercializing innovative neuromodulation solutions for\npatients with cardiovascular diseases. Barostim™ is the first medical\ntechnology approved by FDA that uses neuromodulation to improve the symptoms\nof patients with heart failure. Barostim is an implantable device that\ndelivers electrical pulses to baroreceptors located in the wall of the carotid\nartery. The therapy is designed to restore balance to the autonomic nervous\nsystem and thereby reduce the symptoms of heart failure. Barostim received the\nFDA Breakthrough Device designation and is FDA-approved for use in heart\nfailure patients in the U.S. It has been certified as compliant with the EU\nMedical Device Regulation (MDR) and holds CE Mark for heart failure and\nresistant hypertension in the European Economic Area. To learn more about\nBarostim, visit www.cvrx.com.\n\nInvestor Contact:\nMark Klausner \nICR Healthcare\n443-213-0501\nir@cvrx.com\n\nMedia Contact:\nEmily Meyers \nCVRx, Inc. \n763-416-2853\nemeyers@cvrx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/04c4feba-7841-4ac8-8ca5-6c03be383a0e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1CkbQL-20261022","title":"CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026","author":"Globe Newswire","ticker":"CVRX","created":"2026-10-22T20:30:00.261Z","tickers":["CVRX"],"exchange":"NASDAQ","article_body":"MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX)\n(\"CVRx\"), a commercial-stage medical device company focused on developing,\nmanufacturing and commercializing innovative neuromodulation solutions for\npatients with cardiovascular diseases, today announced that it plans to\nrelease third quarter 2026 financial and operating results after market close\non Thursday, Nov. 5, 2026. The Company will host a conference call to review\nits results at 4:30 p.m. Eastern Time the same day.\n\nA live webcast of the investor conference call will be available online at the\ninvestor relations page of the Company’s website at ir.cvrx.com\n(https://www.globenewswire.com/Tracker?data=zbDHhvjFdAqnHPL9dXgOVeF-QBSw1NRH1u0aOntIMsGOR5KtUJdnBEdcipZwstN__E0nUP-3HqX6ZbqlIZnjPfNS-TBoKeIo_nzMAYF753s=).\nTo listen to the conference call on your telephone, please dial 1-\n877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers,\napproximately ten minutes prior to the start time.\n\nAbout CVRx, Inc.\nCVRx is a commercial-stage medical device company focused on developing,\nmanufacturing and commercializing innovative neuromodulation solutions for\npatients with cardiovascular diseases. Barostim™ is the first medical\ntechnology approved by FDA that uses neuromodulation to improve the symptoms\nof patients with heart failure. Barostim is an implantable device that\ndelivers electrical pulses to baroreceptors located in the wall of the carotid\nartery. The therapy is designed to restore balance to the autonomic nervous\nsystem and thereby reduce the symptoms of heart failure. Barostim received the\nFDA Breakthrough Device designation and is FDA-approved for use in heart\nfailure patients in the U.S. It has been certified as compliant with the EU\nMedical Device Regulation (MDR) and holds CE Mark for heart failure and\nresistant hypertension in the European Economic Area. To learn more about\nBarostim, visit www.cvrx.com.\n\nInvestor Contact:\nMark Klausner \nICR Healthcare\n443-213-0501\nir@cvrx.com\n\nMedia Contact:\nEmily Meyers \nCVRx, Inc. \n763-416-2853\nemeyers@cvrx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/04c4feba-7841-4ac8-8ca5-6c03be383a0e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-22T20:30:00.294183388Z","server_sent_at_ms":1792701000294},"received_at":"2026-10-22T20:30:00.367Z","source_url":null},"analysis":{"id":"165723","press_release_id":"177794","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"CVRx announced it will release third quarter 2026 financial and operating results after market close on Thursday, November 5, 2026.\n\nThe company will host a conference call at 4:30 p.m. ET the same day, with a live webcast available on its investor relations site.\n\nThis is a scheduling notice only and contains no financial figures or guidance.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Earnings-date notice for CVRx -- calendar event only, no results."},"keyFigures":{},"namedEntities":{"people":[{"name":"Mark Klausner","role":"investor contact, ICR Healthcare"},{"name":"Emily Meyers","role":"media contact, CVRx"}],"products":["Barostim"],"companies":[{"name":"CVRx, Inc.","ticker":"CVRX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a routine earnings-date scheduling notice with no financial results, guidance, or operational data. No new information about CVRx's business."},"tickerRelevance":{"others":[],"primary":"CVRX"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings-date-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"CVRx announced it will release third quarter 2026 financial and operating results after market close on Thursday, November 5, 2026.\n\nThe company will host a conference call at 4:30 p.m. ET the same day, with a live webcast available on its investor relations site.\n\nThis is a scheduling notice only and contains no financial figures or guidance.","key_figures":{},"named_entities":{"people":[{"name":"Mark Klausner","role":"investor contact, ICR Healthcare"},{"name":"Emily Meyers","role":"media contact, CVRx"}],"products":["Barostim"],"companies":[{"name":"CVRx, Inc.","ticker":"CVRX"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-22T20:30:03.590Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings-date-notice","issuerAuthored":true}},"durationMs":3185,"modelName":"glm-5.3-flashx"}}